Back to Search Start Over

Maresin-1 Ameliorates Sepsis-Induced Microglial Activation Through Modulation of the P38 MAPK Pathway.

Authors :
Dai M
Sun S
Dai Y
Dou X
Yang J
Chen X
Yang D
Lin Y
Source :
Neurochemical research [Neurochem Res] 2024 Nov 20; Vol. 50 (1), pp. 26. Date of Electronic Publication: 2024 Nov 20.
Publication Year :
2024

Abstract

Sepsis is a life-threatening disease characterized by a dysregulated immune response to infection, often leading to neuroinflammation. As a known immunomodulator, Maresin-1 (MaR1) may have potential applications in the treatment of sepsis-induced neuroinflammation, but its effects in this context are unknown. We used a mouse cecum ligation and puncture (CLP)-induced sepsis model and an in vitro lipopolysaccharide (LPS)-induced neuroinflammatory model of BV2 microglia. Expression of microglial cell markers (IBA1, CD11B, CD68, CD86 and CD206) and pro-inflammatory markers (iNOS and COX2) was assessed. The role of MaR1 in regulating the P38 MAPK pathway was explored using the P38 MAPK inhibitor SB203580. In the CLP model, an increased proportion of M1-type microglia was observed, and MaR1 was able to reverse it. However, the combination of SB203580 and MaR1 did not enhance the therapeutic effect compared to SB20580 alone. In vitro experiments, MaR1 inhibited LPS-induced P38 MAPK nuclear translocation and decreased the expression of pro-inflammatory markers such as iNOS and COX2. As with the animal results, no stacking effect could be obtained with the co-administration of SB203580 and MaR1. Our findings suggest that MaR1 attenuates sepsis-induced neuroinflammation mainly by inhibiting phosphorylation of P38 MAPK in microglial cells. This suggests that MaR1 may have a potential therapeutic role in the treatment of sepsis neuroinflammation.<br />Competing Interests: Declarations. Ethical Approval: All experimental procedures were approved by the Ethics Committee for Animal Experiments of Huazhong University of Science and Technology and were performed in accordance with the standards for the care and use of laboratory animals at this institution. Competing Interests: The authors declare no competing interests.<br /> (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1573-6903
Volume :
50
Issue :
1
Database :
MEDLINE
Journal :
Neurochemical research
Publication Type :
Academic Journal
Accession number :
39565476
Full Text :
https://doi.org/10.1007/s11064-024-04280-z